HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

AbstractOBJECTIVE:
Neuropsychiatric events occur unpredictably in systemic lupus erythematosus (SLE) and most biomarker associations remain to be prospectively validated. This study examined a disease inception cohort of 1047 SLE patients to determine which autoantibodies at enrolment predicted subsequent neuropsychiatric events.
METHODS:
Patients with a recent SLE diagnosis were assessed prospectively for up to 10 years for neuropsychiatric events using the American College of Rheumatology case definitions. Decision rules of graded stringency determined whether neuropsychiatric events were attributable to SLE. Associations between the first neuropsychiatric event and baseline autoantibodies (lupus anticoagulant (LA), anticardiolipin, anti-β(2) glycoprotein-I, anti-ribosomal P and anti-NR2 glutamate receptor) were tested by Cox proportional hazards regression.
RESULTS:
Disease duration at enrolment was 5.4 ± 4.2 months, follow-up was 3.6 ± 2.6 years. Patients were 89.1% female with mean (±SD) age 35.2 ± 13.7 years. 495/1047 (47.3%) developed one or more neuropsychiatric event (total 917 events). Neuropsychiatric events attributed to SLE were 15.4% (model A) and 28.2% (model B). At enrolment 21.9% of patients had LA, 13.4% anticardiolipin, 15.1% anti-β(2) glycoprotein-I, 9.2% anti-ribosomal P and 13.7% anti-NR2 antibodies. LA at baseline was associated with subsequent intracranial thrombosis (total n=22) attributed to SLE (model B) (HR 2.54, 95% CI 1.08 to 5.94). Anti-ribosomal P antibody was associated with subsequent psychosis (total n=14) attributed to SLE (model B) (HR 3.92, 95% CI 1.23 to 12.5, p=0.02). Other autoantibodies did not predict neuropsychiatric events.
CONCLUSION:
In a prospective study of 1047 recently diagnosed SLE patients, LA and anti-ribosomal P antibodies are associated with an increased future risk of intracranial thrombosis and lupus psychosis, respectively.
AuthorsJ G Hanly, M B Urowitz, L Su, S-C Bae, C Gordon, A Clarke, S Bernatsky, A Vasudevan, D Isenberg, A Rahman, D J Wallace, P R Fortin, D Gladman, J Romero-Diaz, J Romero-Dirz, J Sanchez-Guerrero, M A Dooley, I Bruce, K Steinsson, M Khamashta, S Manzi, R Ramsey-Goldman, G Sturfelt, O Nived, R van Vollenhoven, M Ramos-Casals, C Aranow, M Mackay, K Kalunian, G S Alarcón, B J Fessler, G Ruiz-Irastorza, M Petri, S Lim, D Kamen, C Peschken, V Farewell, K Thompson, C Theriault, J T Merrill
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 70 Issue 10 Pg. 1726-32 (Oct 2011) ISSN: 1468-2060 [Electronic] England
PMID21893582 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Autoantibodies
  • Biomarkers
  • Lupus Coagulation Inhibitor
  • Ribosomal Proteins
Topics
  • Adult
  • Autoantibodies (blood)
  • Biomarkers (blood)
  • Epidemiologic Methods
  • Female
  • Humans
  • Intracranial Thrombosis (epidemiology, etiology)
  • Lupus Coagulation Inhibitor (blood)
  • Lupus Erythematosus, Systemic (complications, diagnosis, immunology)
  • Male
  • Mental Disorders (diagnosis, epidemiology, etiology)
  • Middle Aged
  • Prognosis
  • Psychotic Disorders (epidemiology, etiology)
  • Ribosomal Proteins (immunology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: